Regional chemotherapy of neoplastic diseases

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/25399/1/0000848.pd

Gastroduodenal Ulcerations in Patients Receiving Selective Hepatic Artery Infusion Chemotherapy

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72124/1/j.1572-0241.1985.tb02137.x.pd

Improved regional selectivity of hepatic arterial mitomycin by starch microspheres

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109929/1/cptclpt1983163.pd

Constant intraperitoneal 5‐fluorouracil infusion through a totally implanted system

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109794/1/cptclpt198412.pd

Multicenter phase II study of brequinar sodium in patients with advanced lung cancer

A total of 53 patients with advanced lung cancer [non-small-cell (NSC), 21; small-cell (SC), 32] were treated with brequinar sodium. All of the NSC patients were chemotherapy-naive, but 31/32 (97%) SC patients had failed a multiagent chemotherapy program prior to study entry. Brequinar was given intravenously at a median weekly dose of 1200 mg/m 2 . The toxicity was moderate, with 19 patients (36%) experiencing grade 3 or 4 toxicity. Objective responses were observed in one NSC and two SC patients. We conclude that at this dose and on this schedule, brequinar does not have sufficient activity in patients with NSC or in patients with previously treated SC to warrant further evaluation. However, since responses were observed in previously treated SC lung-cancer patients, further evaluation in chemotherapy-naive patients may be warranted.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46927/1/280_2004_Article_BF00685878.pd

Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck

A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m 2 . The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46923/1/280_2004_Article_BF00685106.pd

Evaluation of focal hepatic masses: a comparative study of MRI and CT

We evaluated suspected hepatic lesions in 30 patients using both nongated spin-echo magnetic resonance imaging (MRI) on a 0.35 T superconducting magnet and contrast-enhanced dynamic incremental computed tomography (CT). In the 27 patients with focal lesions, both modalities detected abnormalities in 26 patients. Liver lesions were equally well demonstrated using MRI and CT in 15 patients, better demonstrated by CT in 11 patients, and better demonstrated by MRI in 1 patient. Small lesions (<2 cm) were much better demonstrated using CT than MRI; this was significant when knowledge of the precise extent of disease was necessary for planning surgical therapy or for evaluating response to chemotherapy. Five patients had significant extrahepatic disease detected by CT; MRI identified extrahepatic abnormalities in only 2 of these 5 patients. We conclude that at the current time CT is more useful than nongated spin-echo MRI in the evaluation of suspected hepatic masses.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/48127/1/261_2005_Article_BF02035086.pd